Antigen News and Research

RSS

Discovery answers why mother's immune system does not reject developing fetus as foreign tissue

Researchers at NYU School of Medicine have made an important discovery that partially answers the long-standing question of why a mother's immune system does not reject a developing fetus as foreign tissue.

8 Jun 2012

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Biovest International, Inc., a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., today announced that the U.S. National Cancer Institute (NCI) presented long-term (median 10-year follow-up) outcomes at the 2012 American Society of Clinical Oncology Annual Meeting (ASCO 2012) from a Phase II BiovaxID lymphoma vaccine clinical trial.

8 Jun 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment of 40 patients in the second of three dose cohorts in Lm-LLO-E7-07, a randomized, single blind, placebo controlled Phase 2 dose escalation study assessing the safety and efficacy of ADXS-HPV for the treatment of cervical intraepithelial neoplasia (CIN) 2/3.

7 Jun 2012

InVitria receives new SBIR grant from NIAID

Ventria Bioscience today announced that its non-therapeutic products division InVitria has been awarded a new Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

6 Jun 2012

New immune response data from Generex’s AE37 Phase II trial on breast cancer

Generex Biotechnology Corporation announced today that new immune response data from the on-going Phase II clinical trial of the AE37 breast cancer vaccine undertaken by Generex wholly-owned subsidiary Antigen Express, Inc. was presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2, 2012 in Chicago, IL.

6 Jun 2012

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

OncoGenex Pharmaceuticals, Inc. announced today data from a Phase 2 study of its investigational compound OGX-427 in chemotherapy-naive metastatic castration resistant prostate cancer (mCRPC) patients will be presented during an oral presentation at the 2012 American Society of Clinical Oncology (ASCO) annual meeting on Tuesday, June 5.

5 Jun 2012

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer.

5 Jun 2012

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Millennium: The Takeda Oncology Company with its parent company Takeda Pharmaceutical Company Limited today announced updated results from a phase 2 study of orteronel, a selective oral 17,20 lyase inhibitor, dosed without prednisone in patients with non-metastatic castration resistant prostate cancer (nmCRPC) and rising prostate-specific antigen.

5 Jun 2012

Polynoma initiates POL 103A Phase III trial in melanoma

Polynoma LLC, a U.S. oncology-focused biopharmaceutical company within Hong Kong-based CK Life Sciences Int'l., today announced the start of a Phase III clinical trial program for POL 103A, the Company's novel melanoma vaccine. Polynoma's global, multi-center, double-blind, placebo-controlled Melanoma Antigen Vaccine Immunotherapy Study (MAVIS) is designed to enroll a total of 1059 patients with resected Stage IIb, IIc or III melanoma.

4 Jun 2012

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, will update preliminary data on the safety and clinical benefit of ADXS-HPV from an ongoing randomized Phase 2 trial of ADXS-HPV with or without cisplatin in Indian women with recurrent/refractory cervical cancer who have failed cytotoxic therapy in a poster titled "ADXS11-001 immunotherapy targeting HPV-E7: Preliminary survival data from a phase II study in Indian women with recurrent/refractory cervical cancer" at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting held in Chicago, IL, on Sunday, June 3, 2012.

4 Jun 2012

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Many men with metastatic, hormone-sensitive prostate cancer live longer on continuous androgen-deprivation therapy (also known as hormone therapy) than on intermittent therapy, according to a seventeen-year study led by SWOG, a cancer research cooperative group funded by the National Cancer Institute (NCI).

4 Jun 2012

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Investigators at The Cancer Institute of New Jersey (CINJ) have partnered with the National Cancer Institute (NCI) and launched a clinical trial examining the effectiveness of a combined vaccine and hormone treatment for prostate cancer that is resistant to hormone therapy and not visible on imaging tests such as a CT scan and a bone scan.

2 Jun 2012

Electronic nose and optoacoustics improve diagnosis of prostate cancer

Chances of survival of prostate cancer depend strongly on the stage at which the disease is diagnosed. Now scientists have developed new methods relying on an electronic nose and optoacoustics to improve the diagnosis techniques and avoid fatal treatment delays

2 Jun 2012

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

ImmunoCellular Therapeutics, Ltd., announced today it will present new data from the previously completed Phase I clinical trial of ICT-107, the Company's lead cancer vaccine candidate for the treatment of glioblastoma multiforme (GBM), at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, IL.

1 Jun 2012

MD Bioproducts launches new subtype specific antibody as marker for AS

MD Bioproducts launches a new subtype specific antibody as a marker for ankylosing spondylitis (AS): HLA-B*2705. The anti-HLA-B*2705 antibody, clone MARB4, has been validated for use in flow cytometry, tissue staining and immunoprecipitation.

30 May 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 trial for cervical cancer

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced today that it has completed enrollment in Lm-LLO-E7-15, the 110 patient, randomized Phase 2 trial of ADXS-HPV in women with recurrent/refractory cervical cancer who have failed cytotoxic therapy.

29 May 2012

Scientists develop super-sensitive test that could detect diseases earlier

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

Ultra-sensitive test can diagnose diseases in their earliest stages

Scientists have developed an ultra-sensitive test that should enable them to detect signs of a disease in its earliest stages, in research published today in the journal Nature Materials.

28 May 2012

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

City of Hope was granted a $5,217,004 early translational research award by the California Institute for Regenerative Medicine (CIRM) to support the development of a T cell-based immunotherapy that re-directs a patient's own immune response against glioma stem cells.

28 May 2012

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

DiagnoCure Inc., a Quebec life sciences company that develops and commercializes high-value cancer diagnostic tests, reported that the PROGENSA PCA3 prostate cancer diagnostic test has been featured in a number of presentations and discussions at the American Urological Association (AUA) meeting in Atlanta, GA.

25 May 2012

Antigen News and Research

Discovery answers why mother's immune system does not reject developing fetus as foreign tissue

NCI presents long-term outcomes from BiovaxID lymphoma vaccine Phase II trial at ASCO 2012

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 study on CIN 2/3

InVitria receives new SBIR grant from NIAID

New immune response data from Generex’s AE37 Phase II trial on breast cancer

OncoGenex announces data from OGX-427 Phase 2 study on mCRPC

Seattle Genetics, Agensys announce interim data from ASG-5ME phase I trial on CRPC

Takeda announces updated results from orteronel phase 2 study on nmCRPC

Polynoma initiates POL 103A Phase III trial in melanoma

Advaxis to update preliminary data on ADXS-HPV Phase 2 trial for cervical cancer

Many men with metastatic prostate cancer live longer on continuous hormone therapy

Clinical trial to examine effectiveness of combined vaccine and hormone treatment for prostate cancer

Electronic nose and optoacoustics improve diagnosis of prostate cancer

ImmunoCellular to present new data from ICT-107 Phase I trial on GBM

MD Bioproducts launches new subtype specific antibody as marker for AS

Enrollment complete in Advaxis’ ADXS-HPV Phase 2 trial for cervical cancer

Scientists develop super-sensitive test that could detect diseases earlier

Ultra-sensitive test can diagnose diseases in their earliest stages

City of Hope receives CIRM grant to develop T cell-based immunotherapy against glioma

DiagnoCure’s PCA3 prostate cancer diagnostic test showcased at AUA meeting

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News